- Home
- EKSO vs HOOK Comparison
EKSO vs HOOK Comparison
Compare EKSO & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- HOOK
- Stock Information
- Founded
- EKSO 2005
- HOOK 2011
- Country
- EKSO United States
- HOOK United States
- Employees
- EKSO N/A
- HOOK N/A
- Industry
- EKSO Medical/Dental Instruments
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- HOOK Health Care
- Exchange
- EKSO Nasdaq
- HOOK Nasdaq
- Market Cap
- EKSO 11.6M
- HOOK 9.3M
- IPO Year
- EKSO N/A
- HOOK 2019
- Fundamental
- Price
- EKSO $0.44
- HOOK $0.85
- Analyst Decision
- EKSO Strong Buy
- HOOK Buy
- Analyst Count
- EKSO 2
- HOOK 4
- Target Price
- EKSO $5.00
- HOOK $10.67
- AVG Volume (30 Days)
- EKSO 107.1K
- HOOK 38.5K
- Earning Date
- EKSO 05-06-2025
- HOOK 05-08-2025
- Dividend Yield
- EKSO N/A
- HOOK N/A
- EPS Growth
- EKSO N/A
- HOOK N/A
- EPS
- EKSO N/A
- HOOK N/A
- Revenue
- EKSO $17,925,000.00
- HOOK $43,946,000.00
- Revenue This Year
- EKSO $25.17
- HOOK N/A
- Revenue Next Year
- EKSO $37.02
- HOOK N/A
- P/E Ratio
- EKSO N/A
- HOOK N/A
- Revenue Growth
- EKSO N/A
- HOOK 118.32
- 52 Week Low
- EKSO $0.34
- HOOK $0.72
- 52 Week High
- EKSO $1.53
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- EKSO 55.45
- HOOK 39.54
- Support Level
- EKSO $0.39
- HOOK $0.73
- Resistance Level
- EKSO $0.43
- HOOK $0.85
- Average True Range (ATR)
- EKSO 0.04
- HOOK 0.08
- MACD
- EKSO 0.01
- HOOK 0.03
- Stochastic Oscillator
- EKSO 92.45
- HOOK 77.25
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.